Search results
Results from the WOW.Com Content Network
Lecanemab was jointly developed by Eisai and Biogen. It was granted accelerated approval for medical use in the United States in January 2023, [ 27 ] and fully approved by the FDA in July 2023. [ 24 ] [ 28 ] Lecanemab was approved for medical use in South Korea in May 2024, [ 29 ] and in Mexico in December 2024.
Lecanemab, sold under the brand name Leqembi, is a monoclonal antibody medication used for the treatment of Alzheimer's disease. [ 2 ] [ 4 ] Lecanemab is an amyloid beta -directed antibody. [ 2 ] It is given via intravenous infusion to patients with mild cognitive impairment or mild dementia. [ 2 ]
My memory assessments have been unchanged since I started on lecanemab.” The retired business executive first noticed problems with his memory in 2016, when he was finding it difficult to absorb ...
(Reuters) -The U.S. Food and Drug Administration will expedite its review of Eisai Co Ltd's and Biogen Inc's experimental Alzheimer's drug lecanemab, with a decision due by Jan 6, 2023, the ...
Lecanemab was associated with a type of brain swelling in 12.6% of trial patients, a side effect previously seen with similar drugs. 17.3% of patients had microhemorrhages in the brain— a ...
[33] [34] The phase 3 clinical trials also reported infusion related reactions, amyloid-related imaging abnormalities and headaches as the most common side effects of Lecanemab. In July 2023 the FDA gave Lecanemab full approval for the treatment of Alzheimer's Disease [35] and it was given the commercial name Leqembi.
For premium support please call: 800-290-4726 more ways to reach us
Here are links to possibly useful sources of information about Lecanemab. PubMed provides review articles from the past five years (limit to free review articles ) The TRIP database provides clinical publications about evidence-based medicine .